^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    VeriStrat®

    Company:
    Biodesix
    Type:
    Laboratory Developed Test
    Related tests:
    VeriStrat® provides a personalized view of each patient's disease state within 72 hours. Test results are predictive of outcomes, independent of ECOG performance status, mutation status, PD-L1 expression, and treatment choice. It is a blood-based proteomic test that provides a personalized view of each patient's disease state. It measures acute phase proteins and the acute phase response which indicates chronic inflammation and a more aggressive cancer.
    Cancer:
    Non Small Cell Lung Cancer
    Gene:
    EGFR (Epidermal growth factor receptor), PD-L1 (Programmed death ligand 1)
    Method:
    PCR
    Confirmatory trial(s)
    INSIGHT
    ,
    NCT03289780
    |
    Br J Cancer